MATUCCI, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.207
EU - Europa 3.303
AS - Asia 2.661
SA - Sud America 318
AF - Africa 67
OC - Oceania 28
Continente sconosciuto - Info sul continente non disponibili 1
Totale 10.585
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.129
RU - Federazione Russa 1.073
PL - Polonia 807
SG - Singapore 739
CN - Cina 726
IT - Italia 574
HK - Hong Kong 351
VN - Vietnam 263
BR - Brasile 244
KR - Corea 202
IE - Irlanda 166
SE - Svezia 153
FR - Francia 100
DE - Germania 94
GB - Regno Unito 91
IN - India 83
FI - Finlandia 80
BD - Bangladesh 49
JO - Giordania 49
ID - Indonesia 46
JP - Giappone 44
CH - Svizzera 37
CA - Canada 33
NL - Olanda 32
AR - Argentina 29
AU - Australia 27
ES - Italia 24
MX - Messico 24
BE - Belgio 16
IQ - Iraq 14
UA - Ucraina 14
ZA - Sudafrica 13
NG - Nigeria 11
AE - Emirati Arabi Uniti 10
CI - Costa d'Avorio 10
IL - Israele 10
PK - Pakistan 10
CO - Colombia 9
EC - Ecuador 9
MA - Marocco 9
TR - Turchia 9
VE - Venezuela 9
AT - Austria 8
EG - Egitto 8
PH - Filippine 8
CL - Cile 6
CZ - Repubblica Ceca 6
JM - Giamaica 6
LT - Lituania 6
PY - Paraguay 6
SA - Arabia Saudita 6
TN - Tunisia 6
UZ - Uzbekistan 6
MY - Malesia 5
NP - Nepal 5
TH - Thailandia 5
BJ - Benin 4
PA - Panama 4
UY - Uruguay 4
AZ - Azerbaigian 3
HU - Ungheria 3
OM - Oman 3
RO - Romania 3
AL - Albania 2
BG - Bulgaria 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
GR - Grecia 2
GT - Guatemala 2
HN - Honduras 2
HR - Croazia 2
KG - Kirghizistan 2
PT - Portogallo 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
AM - Armenia 1
AO - Angola 1
BB - Barbados 1
BH - Bahrain 1
BO - Bolivia 1
CR - Costa Rica 1
GE - Georgia 1
IR - Iran 1
KE - Kenya 1
KW - Kuwait 1
KZ - Kazakistan 1
LB - Libano 1
LK - Sri Lanka 1
LU - Lussemburgo 1
LV - Lettonia 1
MD - Moldavia 1
MM - Myanmar 1
MN - Mongolia 1
NC - Nuova Caledonia 1
NI - Nicaragua 1
PE - Perù 1
QA - Qatar 1
RS - Serbia 1
SV - El Salvador 1
SY - Repubblica araba siriana 1
Totale 10.582
Salva come PNG Salva come JPEG
Città #
Warsaw 802
Santa Clara 796
Ashburn 650
Singapore 532
Hong Kong 301
Fairfield 278
San Jose 211
Seoul 202
Hefei 183
Chandler 178
Dublin 166
Beijing 126
Houston 107
Woodbridge 107
Seattle 106
Wilmington 106
Cambridge 103
Ann Arbor 93
Florence 91
Elk Grove Village 88
Ho Chi Minh City 79
Los Angeles 75
Milan 67
Council Bluffs 65
Altamura 63
Lawrence 63
Buffalo 62
Moscow 62
New York 61
Hanoi 60
Dallas 56
Munich 55
Lauterbourg 50
The Dalles 40
Princeton 39
Shanghai 39
Kent 38
Helsinki 35
Jakarta 33
Mumbai 32
Boston 29
Paris 26
Rome 25
Dong Ket 24
Melbourne 23
London 22
San Diego 21
Tokyo 21
São Paulo 20
Turku 20
Medford 19
Bern 18
Luni 18
Frankfurt am Main 17
Boardman 16
Chicago 15
Brussels 14
Clifton 14
Lappeenranta 14
Zurich 14
Chennai 13
Madrid 13
Orem 13
Phoenix 12
Toronto 12
Abuja 11
Abidjan 10
Bengaluru 10
Guangzhou 10
Naples 10
Osaka 10
Johannesburg 9
Montreal 9
Tel Aviv 9
Xi'an 9
Brooklyn 8
Norwalk 8
Redondo Beach 8
Da Nang 7
Hải Dương 7
Liverpool 7
Livorno 7
Tianjin 7
Biên Hòa 6
Campinas 6
Dhaka 6
Genoa 6
Jacksonville 6
Mexico City 6
Ninh Bình 6
Redwood City 6
Salvador 6
Stockholm 6
Tashkent 6
Amman 5
Andover 5
Charlotte 5
Denver 5
Fortaleza 5
Haiphong 5
Totale 7.005
Salva come PNG Salva come JPEG
Nome #
Hapten-Specific TH17 Cells in the Peripheral Blood of β-Lactam-Induced AGEP. 316
Immunoglobulin replacement therapy for yellow nail syndrome 305
Mepolizumab Reduces Inflammatory Eosinophils in Nasal Polyp Tissue and Restores Histological Alterations 288
The in vitro amplification of β-lactam-specific memory t cells improves the diagnostic performance of IGE detection and lymphocyte transformation test 267
Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies 242
Tocilizumab in Giant Cell Arteritis: A Real-Life Retrospective Study 240
Concomitant Bilastine and Montelukast as Additive Therapy for Seasonal Allergic Rhinoconjunctivits and Mild-to-Moderate Asthma. The SKY Study 237
Efficacy and safety of mepolizumab (Anti-Interleukin-5) treatment in Gleich's syndrome 231
The Italian Registry for Primary Immunodeficiencies (Italian Primary Immunodeficiency Network; IPINet): Twenty Years of Experience (1999–2019) 226
Biweekly hizentra® in primary immunodeficiency: A multicenter, observational cohort study (IBIS) 223
Malattia di Anderson-Fabry 219
High proportion of inflammatory CD62Llow eosinophils in blood and nasal polyps of severe asthma patients 218
High serum β-lactams specific/total IgE ratio is associated with immediate reactions to β-lactams antibiotics 208
Assessment of the risk of polyomavirus JC reactivation in patients with immune-mediated diseases during long-term treatment with infliximab 207
Blood CD62Llow inflammatory eosinophils are related to the severity of asthma and reduced by mepolizumab 200
Early experience of an infectious and tropical diseases unit during the coronavirus disease (COVID-19) pandemic, Florence, Italy, February to March 2020 199
Assays and strategies for immunogenicity assessment of biological agents. 194
Skin testing and infliximab-specific antibodies detection as a combined strategy for preventing infusion reaction. 192
Miescher's cheilitis: Surgical management and long term outcome of an extremely severe case. 187
Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency in Routine Clinical Practice: The VISPO Prospective Multicenter Study 185
Autoimmune hepatitis in a patient affected by neuromyelitis optica: A new association. 184
Corrigendum to "Rapid infusions of human normal immunoglobulin 50g/l are safe and well tolerated in immunodeficiencies and immune thrombocytopenia" [Int. Immunopharmacol. 44 (2017) 38-42] 181
Drug-Specific Th2 Cells and IgE Antibodies in a Patient with Anaphylaxis to Rituximab 179
Omalizumab dampens type 2 inflammation in a group of long-term treated asthma patients and detaches IgE from FcεRI 178
Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes 177
The percentage of patients achieving complete remission of urticaria increases with repeated courses of treatment 177
Efficacy and safety of dupilumab in the treatment of CRSwNP in the real-life setting: a review of the literature 176
Subcutaneous Immunoglobulin Twenty Percent Every Two Weeks in Pediatric Patients with Primary Immunodeficiencies: Subcohort Analysis of the IBIS Study 173
The anti-IgE monoclonal antibody omalizumab as adjuvant treatment in desensitization to carboplatin in patients with ovarian cancer 169
Seasonal Allergic Rhinitis Symptoms in Relation to COVID-19 167
Prompt Predicting of Early Clinical Deterioration of Moderate-to-Severe COVID-19 Patients: Usefulness of a Combined Score Using IL-6 in a Preliminary Study 164
Manifestations of Antidrug Antibodies Response: Hypersensitivity and Infusion Reactions. 163
EGPA Phenotyping: Not Only ANCA, but Also Eosinophils 161
Urinary rituximab loss and rate of treatment failure in membranous nephropathy 160
Low-dose mepolizumab effectiveness in patients suffering from eosinophilic granulomatosis with polyangiitis 158
Rapid infusions of human normal immunoglobulin 50g/l are safe and well tolerated in immunodeficiencies and immune thrombocytopenia. 156
Primary antibody deficiencies represent an underestimated comorbidity in asthma patients: efficacy of immunoglobulin replacement therapy in asthma control 153
Effectiveness of tocilizumab in hospitalized moderate-to-severe COVID-19 patients: a real-life study 149
COVID-19 in severe asthmatic patients during ongoing treatment with biologicals targeting type 2 inflammation: Results from a multicenter Italian survey 148
Baseline Eosinophil Count as a Potential Clinical Biomarker for Clinical Complexity in EGPA: A Real-Life Experience 146
Clinical outcome, incidence, and SARS-CoV-2 infection-fatality rates in Italian patients with inborn errors of immunity 146
Long-term retention rate of mepolizumab treatment in severe asthma: a 36-months real-life experience 143
Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice 142
Asthma remission one, none and one-hundred thousand: the relevance of the patient’s view 140
Drug-specific Treg cells are induced during desensitization procedure for rituximab and tocilizumab in patients with anaphylaxis 139
Effectiveness of low-dose intravenous immunoglobulin therapy in minor primary antibody deficiencies: a two-year real-life experience 139
Anti-RuvBL1/2 Autoantibodies Detection in a Patient with Overlap Systemic Sclerosis and Polymyositis 137
Allergological in vitro and in vivo evaluation of patients with hypersensitivity reactions to infliximab. 132
Circulating T cells to infliximab are detectable mainly in treated patients developing anti-drug antibodies and hypersensitivity reactions 132
Alert Card for Patients on Biologicals and Immunosuppressives: An EAACI Position Paper 131
Persistence of both reversible airway obstruction and higher blood eosinophils may predict lung function decline in severe asthma 128
Case Report: A child with NFKB1 haploinsufficiency explaining the linkage between immunodeficiency and short stature 126
Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent 126
Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent 126
Managing Patients with Hypereosinophilic Syndrome: A Statement from the Italian Society of Allergy, Asthma, and Clinical Immunology (SIAAIC) 122
The Kinetics of Antidrug Antibodies, Drug Levels, and Clinical Outcomes in Infliximab-Exposed Patients with Immune-Mediated Disorders 122
Effectiveness and safety of dupilumab in patients with chronic rhinosinusitis with nasal polyps and associated comorbidities: a multicentric prospective study in real life 120
Sustained Efficacy and Low Rate of Adverse Events of Dupilumab in Type‐2 CRSwNP Over 48 Months 114
Asthma phenotype can be influenced by recurrent respiratory infections in patients with primary antibody deficiency: the impact of Ig therapy 96
Mechanisms of Action of Ig Preparations: Immunomodulatory and Anti-Inflammatory Effects 84
Management of patients with chronic rhinosinusitis with nasal polyps (CRSwNP): Results from a survey among allergists and clinical immunologists of the North-west and Center Italy Inter-Regional Sections of SIAAIC and otorhinolaryngologists of National IAR 67
Anti-Rituximab Antibodies Occurrence and Clinical Outcomes in Patients With Primary Membranous Nephropathy 53
Desensitization Protocol for Cemiplimab-Related Infusion Reaction in Cutaneous Squamous Cell Carcinoma: A Case Report and Literature Review 29
A real-life multicenter experience for the post-pandemic management of hypersensitivity reactions to Covid-19 vaccines 17
The Neglected Older Adults in Hereditary Angioedema: Insights From the ITACA Registry 13
null 12
Rituximab in the treatment of anti-HMGCR immune-mediated necrotizing myopathy: Two cases successfully treated 11
Efficacy and safety of mepolizumab in the treatment of CRSwNP in the real-life setting: a review of the literature 9
Dupilumab in Chronic Rhinosinusitis With Nasal Polyps Patients: Impact on Tissue Eosinophilic Inflammation and Eosinophil Subphenotypes 8
Immunogenicity in Fabry Disease: Current Issues, Coping Strategies, and Future Directions 7
Eosinophilic vasculitis of aortic valve in EGPA: a life-threatening onset of disease 4
Totale 10.678
Salva come PNG Salva come JPEG
Categoria #
all - tutte 30.211
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.211
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202143 0 0 0 0 0 0 0 0 0 0 0 43
2021/2022301 5 11 18 11 11 29 18 34 16 24 47 77
2022/2023862 65 186 49 43 51 140 110 48 94 15 32 29
2023/2024519 11 29 61 30 50 56 36 99 14 43 58 32
2024/20252.909 96 282 171 484 713 331 78 185 167 89 123 190
2025/20264.167 545 515 441 416 476 152 473 197 327 319 262 44
Totale 10.678